免疫疗法作为晚期和复发性子宫内膜癌的治疗策略：III期免疫疗法临床试验综述
Immunotherapy as a treatment strategy in advanced stage and recurrent endometrial cancer: review of current phase III immunotherapy clinical trials.
作者信息
Eskander Ramez N, Powell Matthew A
机构信息
Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Oncology, University of California San Diego Moores Cancer Center, 3855 Health Sciences Drive, La Jolla, CA 92093, USA.
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, St. Louis, MO, USA.
出版信息
Ther Adv Med Oncol. 2021 Mar 16;13:17588359211001199. doi: 10.1177/17588359211001199. eCollection 2021.
Abstract
The treatment of advanced stage, metastatic or recurrent endometrial cancer remains a clinically difficult scenario. Although combination carboplatin and paclitaxel is an effective standard-of-care regimen, alternate strategies have shown promise, particularly in biomarker select populations. In an effort to improve oncologic outcomes, investigators are exploring novel immunotherapy combinations. In this review, we discuss the clinical rationale and design of current phase III immuno-oncology clinical trials in patients with advanced stage or recurrent endometrial cancer.
摘要
晚期、转移性或复发性子宫内膜癌的治疗在临床上仍然是一个难题。尽管卡铂和紫杉醇联合使用是一种有效的标准治疗方案，但其他策略也显示出了前景，尤其是在生物标志物选择的人群中。为了改善肿瘤治疗效果，研究人员正在探索新型免疫疗法组合。在这篇综述中，我们讨论了晚期或复发性子宫内膜癌患者当前III期免疫肿瘤学临床试验的临床原理和设计。
相似文献
1
Immunotherapy as a treatment strategy in advanced stage and recurrent endometrial cancer: review of current phase III immunotherapy clinical trials.免疫疗法作为晚期和复发性子宫内膜癌的治疗策略：III期免疫疗法临床试验综述
Ther Adv Med Oncol. 2021 Mar 16;13:17588359211001199. doi: 10.1177/17588359211001199. eCollection 2021.
2
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.卡铂和紫杉醇联合avelumab 对比卡铂和紫杉醇治疗晚期或复发性子宫内膜癌（MITO END-3）：一项多中心、开放标签、随机、对照、Ⅱ期临床试验。
Lancet Oncol. 2023 Mar;24(3):286-296. doi: 10.1016/S1470-2045(23)00016-5. Epub 2023 Feb 14.
3
Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings.辅助及晚期疾病情况下子宫内膜癌的化疗
Oncologist. 2016 Oct;21(10):1250-1259. doi: 10.1634/theoncologist.2016-0062. Epub 2016 Jul 13.
4
PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials.PD-1/PD-L1 抑制剂联合卡铂和紫杉醇与卡铂和紫杉醇治疗原发性晚期或复发性子宫内膜癌的比较：一项随机临床试验的系统评价和荟萃分析。
BMC Cancer. 2023 Nov 29;23(1):1166. doi: 10.1186/s12885-023-11654-z.
5
PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer.用于晚期或复发性子宫内膜癌的PI3K/AKT/mTOR抑制剂
Cochrane Database Syst Rev. 2019 Oct 7;10(10):CD012160. doi: 10.1002/14651858.CD012160.pub2.
6
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.帕博利珠单抗联合仑伐替尼对比化疗用于晚期或复发性子宫内膜癌一线治疗的 III 期、随机、开放标签研究：ENGOT-en9/LEAP-001。
Int J Gynecol Cancer. 2022 Jan;32(1):93-100. doi: 10.1136/ijgc-2021-003017. Epub 2021 Nov 19.
7
Immuno-Oncology for Gynecologic Malignancies.妇科恶性肿瘤的免疫肿瘤学
Adv Exp Med Biol. 2021;1342:193-232. doi: 10.1007/978-3-030-79308-1_6.
8
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC).最大化免疫肿瘤学 III 期临床试验的价值：来自癌症免疫治疗学会（SITC）的清单。
J Immunother Cancer. 2022 Sep;10(9). doi: 10.1136/jitc-2022-005413.
9
Current Status of Clinical Trials for Cervical and Uterine Cancer Using Immunotherapy Combined With Radiation.免疫治疗联合放疗治疗宫颈癌和子宫内膜癌的临床试验现状。
Int J Radiat Oncol Biol Phys. 2021 Feb 1;109(2):396-412. doi: 10.1016/j.ijrobp.2020.09.016. Epub 2020 Sep 15.
10
Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis.英国既往治疗的复发性或晚期子宫内膜癌：一项真实世界观察性分析。
Gynecol Oncol. 2022 Aug;166(2):317-325. doi: 10.1016/j.ygyno.2022.06.011. Epub 2022 Jun 22.
引用本文的文献
1
Advances in Immunotherapy for Endometrial Cancer: Insights into MMR Status and Tumor Microenvironment.子宫内膜癌免疫治疗的进展：对错配修复状态和肿瘤微环境的见解
Cancers (Basel). 2024 Nov 22;16(23):3918. doi: 10.3390/cancers16233918.
2
A comprehensive analysis of CEBPA on prognosis and function in uterine corpus endometrial carcinoma.CEBPA 在子宫体子宫内膜癌中的预后和功能的综合分析。
Sci Rep. 2024 Oct 10;14(1):23773. doi: 10.1038/s41598-024-74242-6.
3
Real-world first-line treatment patterns and outcomes in recurrent/advanced endometrial cancer patients in Europe.在欧洲，复发性/晚期子宫内膜癌患者的一线治疗模式和结局的真实世界研究。
Future Oncol. 2024;20(34):2637-2645. doi: 10.1080/14796694.2024.2379233. Epub 2024 Aug 9.
4
Real-world prevalence of microsatellite instability testing and related status in women with advanced endometrial cancer in Europe.欧洲晚期子宫内膜癌女性中微卫星不稳定性检测及相关情况的真实世界流行率。
Arch Gynecol Obstet. 2024 Jun;309(6):2833-2841. doi: 10.1007/s00404-024-07504-3. Epub 2024 Apr 18.
5
Loss of NLRP3 reduces oxidative stress and polarizes intratumor macrophages to attenuate immune attack on endometrial cancer.NLRP3 缺失可减少氧化应激，并使肿瘤内巨噬细胞极化，从而减弱对子宫内膜癌的免疫攻击。
Front Immunol. 2023 Apr 3;14:1165602. doi: 10.3389/fimmu.2023.1165602. eCollection 2023.
6
PD-L1 Expression in Endometrial Cancer and Its Association with Clinicopathological Features: A Systematic Review and Meta-Analysis.子宫内膜癌中PD-L1表达及其与临床病理特征的关联：一项系统综述和荟萃分析
Cancers (Basel). 2022 Aug 13;14(16):3911. doi: 10.3390/cancers14163911.
7
Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer that are non-microsatellite instability high (non-MSI-high) or mismatch repair proficient (pMMR) in the United States.美国非微卫星高度不稳定（非MSI-H）或错配修复功能正常（pMMR）的晚期子宫内膜癌患者的治疗模式及真实世界临床结局
Gynecol Oncol Rep. 2022 Jun 17;42:101026. doi: 10.1016/j.gore.2022.101026. eCollection 2022 Aug.
8
Polymeric Systems for Cancer Immunotherapy: A Review.聚合物系统在癌症免疫治疗中的应用：综述。
Front Immunol. 2022 Feb 22;13:826876. doi: 10.3389/fimmu.2022.826876. eCollection 2022.
本文引用的文献
1
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.帕博利珠单抗联合仑伐替尼对比化疗用于晚期或复发性子宫内膜癌一线治疗的 III 期、随机、开放标签研究：ENGOT-en9/LEAP-001。
Int J Gynecol Cancer. 2022 Jan;32(1):93-100. doi: 10.1136/ijgc-2021-003017. Epub 2021 Nov 19.
2
Clinical significance of homologous recombination deficiency score testing in endometrial Cancer.同源重组缺陷评分检测在子宫内膜癌中的临床意义。
Gynecol Oncol. 2021 Mar;160(3):777-785. doi: 10.1016/j.ygyno.2020.12.010. Epub 2021 Feb 6.
3
Cancer Statistics, 2021.癌症统计数据，2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
4
Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).卡铂和紫杉醇治疗晚期子宫内膜癌：一项 III 期试验（NRG Oncology/GOG0209）的最终总生存和不良事件分析。
J Clin Oncol. 2020 Nov 20;38(33):3841-3850. doi: 10.1200/JCO.20.01076. Epub 2020 Sep 29.
5
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.随机 II 期临床试验：卡铂-紫杉醇与卡铂-紫杉醇-曲妥珠单抗治疗过度表达 Her2/Neu（NCT01367002）的晚期（III-IV 期）或复发性子宫浆液性癌：总生存分析更新。
Clin Cancer Res. 2020 Aug 1;26(15):3928-3935. doi: 10.1158/1078-0432.CCR-20-0953. Epub 2020 Jun 29.
6
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.帕博利珠单抗治疗非结直肠癌高度微卫星不稳定/错配修复缺陷型癌症患者的疗效：来自 II 期 KEYNOTE-158 研究的结果。
J Clin Oncol. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. Epub 2019 Nov 4.
7
Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial.卡铂-紫杉醇与卡铂-紫杉醇-贝伐珠单抗治疗晚期或复发性子宫内膜癌的比较：MITO END-2 - 一项随机 II 期试验。
Gynecol Oncol. 2019 Dec;155(3):406-412. doi: 10.1016/j.ygyno.2019.10.013. Epub 2019 Oct 31.
8
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.Avelumab 治疗错配修复缺陷型和错配修复功能完整型复发性/持续性子宫内膜癌的 II 期研究。
J Clin Oncol. 2019 Oct 20;37(30):2786-2794. doi: 10.1200/JCO.19.01021. Epub 2019 Aug 28.
9
The rationale for including immune checkpoint inhibition into multimodal primary treatment concepts of head and neck cancer.将免疫检查点抑制纳入头颈癌多模式初始治疗方案的基本原理。
Cancers Head Neck. 2016 Aug 10;1:8. doi: 10.1186/s41199-016-0009-6. eCollection 2016.
10
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.阿替利珠单抗联合贝伐珠单抗对比舒尼替尼用于既往未接受治疗的转移性肾细胞癌患者（IMmotion151）：一项多中心、开放标签、III 期、随机对照临床试验。
Lancet. 2019 Jun 15;393(10189):2404-2415. doi: 10.1016/S0140-6736(19)30723-8. Epub 2019 May 9.
Zotero 插件